Thoracic radiation in combination with erlotinib—results from a phase 2 randomized trial

Thoracic radiation in combination with erlotinib—results from a phase 2 randomized trial

BackgroundRadiotherapy (RT) can be used to reduce symptoms and maintain open airways for patients with non-small cell lung cancer when systemic treatment is not sufficient. For some patients, tumor control is not achieved due to radioresistance. Concurrent inhibition of epidermal growth factor recep...

Full description

Bibliographic Details
Main Authors: Hanne Marte Nymoen, Tine Norman Alver, Henrik Horndalsveen, Hanne Astrid Eide, Maria Moksnes Bjaanæs, Odd Terje Brustugun, Bjørn Henning Grønberg, Vilde Drageset Haakensen, Åslaug Helland
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-08-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
radioresistance
EGFR-inhibitor
erlotinib
adverse events
toxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1412716/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1412716/full

Similar Items